Importantly, in line with DNMT3B KD, we found that AMO-1 and XG-2 c-MYC-overexpressing cells were more sensitive to NA treatment compared to their normal counterparts, suggesting that an active c-MYC transcriptional program sensitizes MM cells to DNMT3B targeting (Figure S8A). The gene discussed is DNMT3B; the disease is Miyoshi myopathy.